Lilly says no higher offer for SGX

Eli Lilly says it won't be sweetening its offer for SGX Pharmaceuticals. The company says its bid of $3 a share, which had doubled the stock's value, was its best and final offer. Shareholders vote August 20. Report

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.